Larvol Delta - Breaking-New-Ground-in-Oncology-FDA-Acceptance-of-Vepdegestrant-NDA-Marks-a-Milestone-for-PROTAC-Therapies-in-Breast-Cancer

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

http://www.ncbi.nlm.nih.gov/pubmed/42411075

JinWei Zhang

Jul 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next